Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics' stock experienced volatility over the past six months. In July 2025, the FDA issued a Complete Response Letter (CRL) for deramiocel, causing a 33% stock drop. In August 2025, the company faced legal challenges. In December 2025, positive Phase 3 HOPE-3 data for deramiocel led to a tripling of shares, securing commercialization agreements with Nippon Shinyaku, and a capital raise of over $160 million. Analysts at Oppenheimer and Piper Sandler raised their price targets. In January 2026, shares experienced a pullback, and Wall Street Zen downgraded the stock from "hold" to "sell."

Capricor Therapeutics does not exhibit typical demand seasonality as its revenue is primarily from collaboration payments and grants. Its financial performance depends on regulatory approvals and the commercial launch of its product candidates. Stock return seasonality reflects market trading patterns rather than seasonal demand for the company's pipeline products.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics and vaccines for diseases with high unmet medical needs. Its lead product candidate is Deramiocel (CAP-1002), an allogeneic cell therapy in Phase 3 development for Duchenne muscular dystrophy (DMD) cardiomyopathy. Capricor is also advancing the StealthX™ exosome technology platform for targeted delivery of therapeutics and exosome-based vaccines.

Capricor Therapeutics, Inc. is headquartered in San Diego, California, United States. The company has commercialization and distribution partnerships for deramiocel in the U.S. and Japan, and is in negotiations for European partnerships, indicating a potential global reach.

Capricor Therapeutics' brand reputation has been influenced by regulatory setbacks, legal challenges, and clinical successes. In early 2025, the company completed its BLA submission and FDA Pre-License Inspection. In mid-2025, the FDA's Complete Response Letter (CRL) and allegations of securities law violations negatively impacted the company's reputation. In late 2025, positive Phase 3 HOPE-3 data and commercial partnerships with Nippon Shinyaku boosted the company's prospects and improved its scientific and clinical reputation, which was further reinforced by subsequent analyst upgrades.

Capricor Therapeutics, Inc. has a diverse ownership structure. Institutional owners hold between 19.01% and 40.73% of shares, with major holders including BlackRock, Inc., Vanguard Group Inc, and Nippon Shinyaku Co., Ltd. Individual investors hold a significant portion, estimated to be around 47% or up to 79.91% when combined with public companies and individual investors. Insiders own between 1.08% and 8.48% of the shares.